

PRESS RELEASE

Cellectis to present at the Annual Congress "Gene Targeting" in Vienna

Paris, February 8, 2011 – Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced today that Philippe Duchateau, PhD, head of the R&D group and Deputy Chief Scientific Officer at Cellectis will present his work at the Gene Targeting Congress to be held in Vienna, Austria, on February 9-12, 2011.

Targeted approaches have emerged today as an alternative to current random insertion strategies for gene therapy. Meganucleases, the most specific endonucleases, represent ideal tools for targeted genome editing, or genome surgery. They can induce up to 20% of gene insertion into chosen human genes.

Dr Duchateau will present "Engineered Meganucleases for Genome Engineering Purposes" on February 10, 2011, at 10:10AM, during an oral session Targeted Integration in Model Species.

For the full program see http://www.vipca.at/gt2011/programme.html

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

More information at www.cellectis.com



Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

For further information, please contact:

Cellectis

Sylvie Delassus
Senior VP Corporate Communication
+ 33 (0)1 41 83 99 00
media@cellectis.com

Alize RP
Caroline Carmagnol
+33 (0) 6 64 18 99 59
caroline@alizerp.com